FOLLOW-UP VISIT PACKET UNIFORM DATA SET (UDS) VERSION 4.0



Form D1a: Clinical Syndrome

ADRC: _	PTID: F	orm date:/_	/ Visit #:	Examiner's initials:			
Langua 1 Eng 2 Spa	lish						
	UCTIONS: This form is to be completed by the clinician. For acommod the clinician of the	lditional clarifica	tion and examples, see the UDS	Coding Guidebook			
1.	Diagnosis method—responses in this form are based on diagonal \square_1 Single clinician \square_2 Formal consensus panel \square_3	•	r more clinicians or other informal <u>c</u>	group)			
Sect	ion 1 – Level of impairment – Unimpaired co	gnition/beha	vior, SCD, MCI/MBI, or de	ementia			
2.	 Does the participant have: Unimpaired cognition (e.g., cognitive performance and functional status (i.e., CDR) judged to be unimpaired)? AND Unimpaired behavior (i.e., the participant does not exhibit behavior sufficient to diagnose MBI – see MBI section starting at Q7) or dementia due to FTLD or LBD and/or FTLD behavior and language domains=0? No (SKIP TO QUESTION 3) 1 Yes (CONTINUE TO QUESTION 2a) Note: For those with longstanding cognitive impairment that does not represent a decline from their usual functioning, consider checking Question 5b for a diagnosis of "Cognitively Impaired, Not MCI/dementia". 						
Subj	ective Cognitive Decline						
2	Does the participant report 1) significant concerns abo2) no neuropsychological evidence of decline AND 3) r			FORM HERE)			
2	b. As a clinician, are you confident that the subjective cog is clinically meaningful?	nitive decline	0 No (END FORM HERE) 1 Yes (END FORM HERE)				
Dem	entia criteria						
Requirement #1: Participant has cognitive or behavioral (neuropsychiatric) symptoms that meet all of the following criteria: Requirement #2: Participant must have impairment in one* or more of the following domains:							
 Interfere with ability to function as before at work or at usual activities Represent a decline from previous levels of functioning Are not explained by delirium or major psychiatric disorder Include cognitive impairment detected and diagnosed through a combination of: 1) history-taking; 2) objective assessment (bedside or neuropsychological testing) Impaired ability to acquire and remember new information impaired reasoning and handling of complex tasks, poor judgment Impaired reasoning and handling of complex tasks, poor judgment Impaired ability to acquire and remember new information in the price of the p							
<i>J</i> .	□ No (CONTINUE TO QUESTION 4) □ 1 Yes (SKIP TO QUESTION 6a)						

naccmail@uw.edu ALZHEIMER'S COORDINATING naccdata.org

Participan	: ID: F	orm date:	/ /	Visit #:				
Section	n 1 – Level of impairment				continued			
MCI cor	e clinical criteria							
Check all	Check all criteria that apply in Q4.							
	4. Clinical concern about decline in cognition compared to participant's prior level of lifelong or usual cognitive function (e.g., based on input from participant, co-participant, and/or the clinician's judgment, CDR SB 0.5+, etc.) 1 Impairment in one or more cognitive domains, compared to participant's estimated prior level of lifelong or usual cognitive function, or supported by objective longitudinal neuropsychological evidence of decline 1 Largely preserved functional independence OR functional dependence that is not related to cognitive decline (e.g., based on clinical judgment)							
If all three criteria are checked, choose 1=Yes for Q4b. If less than 3 criteria are met, choose 0=No for Q4b. If only some of the criteria from Q4 are checked, with the exception of the third MCl criteria alone , consider a diagnosis of cognitively impaired , not MCl/dementia on Q5b. If only the third MCl criteria is met in Q4, select 0=No for Q5b.								
4b.	Does the participant meet all three (amnestic or non-amnestic)?	of the above criteri	a for MCI	O No (CONTINUE TO QUESTION) 1 Yes (SKIP TO QUESTION)				
Cogniti	vely impaired, not MCI/deme	ntia						
impairme	ose of the "Cognitively impaired, not l nt or decline who do not meet forma	l MCI criteria.			nce of cognitive			
	applicable criteria for cognitively	•						
5.								
If any of t	he criteria in Q5 are met choose 1=Ye							
5b. Does the participant meet any criteria for cognitively impaired, not MCI/dementia?								
Affecte	d Domains – Dementia and M	CI						
Choose domains that are impaired at the current visit based on clinical judgment informed by clinical history and neuropsychological testing. <u>Select one or more</u> as Impaired ; all others will default to unimpaired in the NACC database.								
Note on behavior changes : For patients with <i>dementia</i> who have behavior changes, record the presence of behavioral changes here (not in the following MBI section) by marking Q6f as Impaired and skipping the MBI section (SKIP TO Q8). For behavioral changes in the context of an MCI (or as an isolated) symptom, consider a diagnosis of MBI in the next section.								
					Impaired			
6a.	Memory							
6b.	Language				□ ₁			
6с.	Attention							
6d.	Executive							
6e.	Visuospatial				<u></u> 1			
6f.	Behavioral (for participants with dem	entia only; see MBI	for MCI participants,					
6g.	Apraxia				□1			

Section 1 – Level of impairment	continued				
Mild Behavioral Impairment (MBI) core clinical criteria					
 Participant, co-participant, or clinician identifies a change in the participant's affect, motivation, thought content, behavior, or personality that is clearly different from their usual affect, motivation, thought content, behavior, or personality Symptoms have been present at least intermittently for the last six months or longer Late onset (i.e., age > ~50, unless early onset neurodegenerative syndrome is suspected) Not explained by delirium, other psychiatric disorder by DSM criteria (including recent onset, longstanding or recurrence of longstanding disorder). Symptoms interfere with at least one of these: work, interpersonal relationships, social activities Largely preserved independence in other functional abilities (no change from prior manner/level of functioning, or uses minimal aids or assistance) 					
7. Does the participant meet criteria for MBI? (If participant meets criteria for dementia an MBI diagnosis is excluded.)	7a)				
MBI affected domains — <u>Select one or more</u> affected domains (Note: If "Yes" is indicated in any domain below, the participant should have a corresponding symptom checked on Form B9 — Clinicia of Symptoms, either from among the specific symptoms denoted there, or in "other")	an Judgment				
	No Yes				
7a. Motivation (e.g., apathy symptoms on Form B9)	0 1				
7b. Affective regulation (e.g., anxiety, irritability, depression, and/or euphoria symptoms on Form B9)	01				
7c. Impulse control (e.g., obsessions/compulsions, personality change, and/or substance abuse symptoms on Form B9)	□ 0 □ 1				
7d. Social appropriateness (e.g., disinhibition, personality change, and/or loss of empathy symptoms on Form B9)	□0 □1				
7e. Thought content/perception (e.g., delusions and/or hallucinations on Form B9)					
					
Section 2 – Clinical syndrome					
	propriate and plogical				
Section 2 – Clinical syndrome The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is	oropriate and ological s known and				
Section 2 – Clinical syndrome The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome 1 Yes	oropriate and ological s known and				
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No."	oropriate and ological s known and				
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database.	oropriate and ological s known and				
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. 8a. Amnestic predominant syndrome	oropriate and ological s known and				
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. 8a. Amnestic predominant syndrome Bb. Dysexecutive predominant syndrome	oropriate and ological s known and				
The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. 8a. Amnestic predominant syndrome 8b. Dysexecutive predominant syndrome Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome)	oropriate and ological s known and				
Section 2 – Clinical syndrome The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. 8a. Amnestic predominant syndrome 8b. Dysexecutive predominant syndrome 8c. Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome) 8d. Primary progressive aphasia (PPA) syndrome: 8d1. If present, select one: 1 Semantic PPA 2 Logopenic PPA 3 Nonfluent/agrammatic PPA 4 Primary progressive apraxia of speech	oropriate and ological s known and				
Section 2 – Clinical syndrome The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. 8a. Amnestic predominant syndrome 8b. Dysexecutive predominant syndrome 8c. Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome) 8d. Primary progressive aphasia (PPA) syndrome: 8d1. If present, select one: 1 Semantic PPA 2 Logopenic PPA 3 Nonfluent/agrammatic PPA 4 Primary progressive apraxia of speech 5 PPA other/not otherwise specified 8e. Behavioral variant frontotemporal (bvFTD) syndrome	oropriate and ological s known and				
Section 2 – Clinical syndrome The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when app MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information a cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etic Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is may have influenced the clinical diagnosis. 8. Is there a predominant clinical syndrome? Note that the participant may not meet any clinical criteria or may not have a predominant syndrome (for instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." Select the predominant syndrome as present; all others will default to Absent in the NACC database. 8a. Amnestic predominant syndrome 8b. Dysexecutive predominant syndrome 8c. Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome) 8d. Primary progressive aphasia (PPA) syndrome: 8d1. If present, select one: 1 Semantic PPA 2 Logopenic PPA 3 Nonfluent/agrammatic PPA 4 Primary progressive apraxia of speech 5 PPA other/not otherwise specified 8e. Behavioral variant frontotemporal (bvFTD) syndrome	oropriate and ological s known and				

Form date: ____ / ___ / ___ __ __

Participant ID:

Sec	tion	2 – Clinical syndrome					C	ontinued
								Present
8	Bh. Pi	imary supranuclear palsy (PSP) syndrome						□ 1
8h1. If present, select one: 1 Richardson's syndrome criteria 2 Non-Richardson's								
	8i. Traumatic encephalopathy syndrome							□ 1
	8j. Corticobasal syndrome (CBS)						□ 1	
8	3k. M	ultiple system atrophy (MSA) syndrome						□ 1
8k1. If present, select one: 1 MSA-predominant cerebellar ataxia (MSA-C) 2 MSA-predominant Parkinsonism (MSA-P) 3 MSA-predominant dysautonomia								
	8I. O	ther (SPECIFY):	<u> </u>					□ ₁
9.		ate the source(s) of information used to assign the cli	•					
	Selec	t one or more as Yes ; all others will default to No in th	ne NACC da	itabase.				
								Yes
		inical information (history, CDR)						<u></u>
		ognitive testing						
9	9c. Bi	omarkers (MRI, PET, CSF, plasma)						∐1
Sect	ion 3	B – Primary or contributing non-neuro	degene	rative	or non-	CVD condit	ions	
The purpose of Section 3 is to identify conditions or disorders that are present and potentially contributing to the clinical syndrome. This must be filled out for those with cognitive or behavioral impairment (i.e., MCI, MBI, dementia, etc.) Indicate whether a given condition is a primary, contributing, or non-contributing cause of the observed impairment, based on the clinician's best judgment.								
Select one or more condition(s) as Present ; if there are no primary or contributing non-neurodegenerative or non-CVD conditions, leave all conditions blank. All conditions left blank will default to Absent in the NACC database. <i>Only one diagnosis should be selected as 1 = Primary.</i>								
		diagnose a disorder, DSM-5-TR criteria require that sational, or other important areas of functioning. For i					-	
		Condition	Present		Primary	Contributing	Non-c	ontributing
10.	Majo	depressive disorder (DSM-5-TR criteria*)	□ 1	10a.	□ 1	\square_2		□ ₃
11.	Othe	specified depressive disorder (DSM-5-TR criteria*)	□ 1	11a.	□ 1	\square_2		\square_3
12.	Bipol	ar disorder (DSM-5-TR criteria*)	□ 1	12a.	<u> </u>	□ 2		□ 3
13.	Schiz criter	ophrenia or other psychotic disorder (DSM-5-TR ia*)	□ 1	13a.	□ ₁	\square_2		□ ₃
14.	Anxie	ty disorder (DSM-5-TR criteria*)		14a.	□ 1	□ 2		□ ₃
	lf	present, (SPECIFY) (check all that apply):						
	14b.	☐ 1 Generalized anxiety disorder						
	14c.	☐ 1 Panic disorder						
	14d.	1 Obsessive-compulsive disorder (OCD)						
	14e.	1 Other (SPECIFY):						
15.	Post-	traumatic stress disorder (PTSD)(DSM-5-TR criteria*)	□ 1	15a.	□ 1	\square_2		□ 3

Form date: ___ / ___ / ___ __ __

Participant ID:

Participant ID:	Form date:	1 1	Visit #:	
rarticipant ib	ronn date.	/	VISIL #.	

Section 3 – Primary or contributing non-degenerative or non-CVD conditions continued						continued
	Condition	Present		Primary	Contributing	Non-contributing
16.	Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia)	□ 1	16a.	□ 1	□ ₂	□ 3
17.	Delirium (DSM-5-TR criteria*)	□ ₁	17a.	□ 1	\square_2	3
18.	Other psychiatric disorder (DSM-5-TR criteria*)	□ 1	18a.	□ 1	\square_2	□ 3
	18b. If present, (SPECIFY) :					
19.	Traumatic brain injury (Distinct from TES and CTE, which are documented as a Clinical Syndrome and Etiologic Diagnosis, respectively)	□ 1	19a.	□ 1	□ ₂	□ ₃
20.	Epilepsy	□ ₁	20a.	□ 1	□ 2	3
21.	Normal-pressure hydrocephalus	□ 1	21a.	□ 1	\square_2	3
22.	CNS Neoplasm	□ ₁	22a.	□ 1	\square_2	3
22	2b. If present, select one: 1 Benign 2 Malignant					
23.	Human immunodeficiency virus (HIV) infection	□ 1	23a.	□ 1	\square_2	3
24.	Post COVID-19 cognitive impairment	□ 1	24a.	□ 1	\square_2	3
25.	Sleep apnea (i.e., obstructive, central, mixed or complex sleep apnea)	□ ₁	25a.	□ 1	□ ₂	□ 3
26.	Cognitive impairment due to other neurologic, genetic, infectious conditions (<i>not listed above</i>), or systemic disease/medical illness (as indicated on Form A5/D2)	□ 1	26a.	□ 1	<u> </u>	3
26	b. If present, (SPECIFY):					
27.	Cognitive impairment due to alcohol use or abuse	□ ₁	27a.	□ 1	<u></u>	□ 3
28.	Cognitive impairment due to substance use or abuse		28a.	□ 1	\square_2	□ 3
29.	Cognitive impairment due to medications	□ 1	29a.	□ 1	\square_2	3
30.	Cognitive impairment not otherwise specified (NOS)	□ 1	30a.	□ 1	\square_2	□ 3
30	b. If present, (SPECIFY):					
31.	Cognitive impairment not otherwise specified (NOS)	_1	31a.	□ 1	\square_2	3
31	b. If present, (SPECIFY):					
32.	Cognitive impairment not otherwise specified (NOS)	<u></u> 1	32a.	□ 1	_2	3
32	b. If present (SPECIFY):					